We're in the midst of earnings season, and this is a pivotal week for three of the major players in the obesity drug market. Tomorrow, pharmaceutical company VIVUS (NASDAQ:VVUS) will post its first quarterly earnings report since launching its obesity drug, Qsymia. This new therapeutic became available to patients in mid-September, and beat Arena Pharmaceuticals' (NASDAQ:ARNA) rival drug Belviq to market.

Arena will also release its results tomorrow, and Orexigen Therapeutics (NASDAQ: OREX) -- which is still developing its weight loss drug Contrave -- will post its third-quarter results on Wednesday.

In the following video, analyst Max Macaluso and health care bureau chief Brenton Flynn focus on VIVUS and discuss several issues investors should be tuning in for in tomorrow's conference call -- namely Qsymia sales projections, an update on VIVUS' plans to reapply for Qsymia's EU approval, and news regarding this drug's distribution.

Foolish Bottom Line

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.